Trailing-twelve-month (TTM) revenue is $201.11 Billion with a year-over-year growth of +6.27%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $50,711,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-21 |
| Q4 FY2025Period ended 2025-12-31 | $49,747,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-06 |
| Q1 FY2026Period ended 2026-03-31 | $50,181,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-22 |
| Q2 FY2026Period ended 2026-06-30 | $50,474,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-15 |
| TTM revenue | $201,113,000,000 |
Current P/S: $90,696,905,771 market capitalization ÷ $201,113,000,000 TTM revenue = 0.45x.
Market capitalization source: FMP quote. Quote observed 2026-09-10T18:10:20.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $50.47B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-10T18:10:20.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Carelon Services Segment | N/A | N/A | N/A | $96.0B | $53.9B | $71.7B |
| Commercial Specialty Business Segment | $36.7B | $38.8B |
$201.11B
$201.11 Billion
+6.27%
vs. $189.25B a year ago (TTM)
+9.25%
5 Year compound annual growth rate
1 Year
+6.27%
3 Year
+6.67%
5 Year
+9.25%
10 Year
+9.41%
15 Year
+8.49%
20 Year
+7.14%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $199.13B | +$22.32B | +12.62% |
| 2024 | $176.81B | +$5.47B | +3.19% |
| 2023 | $171.34B | +$14.74B | +9.42% |
| 2022 | $156.59B | +$17.96B | +12.95% |
| 2021 | $138.64B | +$16.77B | +13.76% |
| 2020 |
TTM Growth
+6.27%
3-Year CAGR
+6.67%
5-Year CAGR
+9.25%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-10T18:10:20.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
| N/A |
| N/A |
| N/A |
| Government Business Segment | $71.6B | $82.9B | $96.8B | N/A | N/A | N/A |
|---|
| Health Benefits Segment | N/A | N/A | N/A | $148.6B | $150.3B | $167.1B |
|---|
| IngenioRx Segment | $10.4B | $12.8B | $15.0B | N/A | N/A | N/A |
|---|
| Other Segment | $2.2B | $10.3B | $13.3B | $479M | N/A | N/A |
|---|
| Segment Eliminations | N/A | -$20.5B | -$24.6B | -$340M | N/A | -$41.7B |
|---|
| $121.87B |
| +$17.65B |
| +16.94% |
| 2019 | $104.21B | +$12.11B | +13.15% |
| 2018 | $92.11B | +$2.07B | +2.29% |
| 2017 | $90.04B | +$5.06B | +5.96% |
| 2016 | $84.98B | +$5.74B | +7.24% |
